Disseminated strongyloidiasis and cytomegalovirus infection in a patient with anaplastic large cell lymphoma.
Rehman
Jalil Ur
JU
Rao
T Vasudev
TV
AlKindi
Salam
S
Dennison
David
D
Pathare
A V
AV
D000328:Adult; D015766:Albendazole / Q000627:therapeutic use; D000871:Anthelmintics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D019353:Endemic Diseases; D015774:Ganciclovir / Q000627:therapeutic use; D005756:Gastritis / Q000188:drug therapy / Q000209:etiology* / Q000469:parasitology / Q000821:virology; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D017728:Lymphoma, Large-Cell, Anaplastic / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D009850:Oman; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D013322:Strongyloidiasis / Q000188:drug therapy / Q000209:etiology*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D000871:Anthelmintics; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D015766:Albendazole; D015774:Ganciclovir; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate